about
Dissemination of definitions and concepts of allergic and hypersensitivity conditionsHepatic manifestations of non-steroidal inflammatory bowel disease therapyIdiosyncratic adverse drug reactions: current conceptsAssociation of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysisDrug-induced hypersensitivity reaction: A case of simultaneous thyroiditis and fulminant type 1 diabetesSevere skin complications in patients treated with antidepressants: a literature review.Acute generalized exanthematous pustulosis: an unusual side effect of meropenemAnything Rare is Possible: Letrozole Induced Eczematous Skin EruptionClinical features of fixed drug eruption at a tertiary hospital in Korea.HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in EuropeansConcurrence of Stevens-Johnson Syndrome and Bilateral Parotitis after Minocycline Therapy.Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.Immunological principles of T-cell-mediated adverse drug reactions in skin.Drug hypersensitivity: pharmacogenetics and clinical syndromes.20-Hydroxylation is the CYP-dependent and retinoid-inducible leukotriene B4 inactivation pathway in human and mouse skin cellsDRESS syndrome: a case report and literature reviewCategorization of allergic disorders in the new World Health Organization International Classification of Diseases.HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese.Nimesulide induced leukocytoclastic vasculitis and hepatitis: a case report.Drug Eruptions: An 8-year Study Including 106 Inpatients at a Dermatology Clinic in TurkeyCutaneous side effects of antiosteoporosis treatments.Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibioticsCurrent understanding of delayed anticonvulsant hypersensitivity reactions.Eosinophilia: secondary, clonal and idiopathic.Testing for drug hypersensitivity syndromes.Drug rash with eosinophilia and systemic symptoms syndrome: sex and the causative agent.Stevens-Johnson syndrome: pathogenesis, diagnosis, and management.Pharmacogenetic information derived from analysis of HLA alleles.Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11.Pharmacogenomics in clinical practice and drug development.HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.Genetic predisposition of life-threatening antiepileptic-induced skin reactions.Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method.Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper.Acute generalised exanthematous pustulosis.Anticonvulsant hypersensitivity syndrome: an update.T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China.Tests for evaluating non-immediate allergic drug reactions.
P2860
Q26739766-D7C28AEE-C0DF-43E1-8B54-D7167751D76FQ26773684-65BDFB19-835B-4545-A99D-646E61D2EA90Q26824391-171D1534-D8A4-4474-845A-9D8CF075F446Q26853305-B08C321D-3A83-4C5D-8404-C7053BD94AC5Q33441594-5DD08048-C702-4B2F-B66D-18DE871D68DBQ33955626-25F58765-D3D2-4BDD-9708-64B42DE3D37BQ34023005-59BE763A-6FCE-4DB5-98D8-17C044A92BB0Q34030565-E6D301E8-05BB-4332-BD31-9652AE8511A7Q34167916-57958117-9E8F-4A2C-988C-94839672E837Q34172669-8095FDD5-EFD3-432F-A334-52CDA239677BQ34336053-09D2D9F9-4C78-4455-9599-7C1703C232D7Q34594695-4BEF31CC-A1A4-4E19-84A0-3A12D82B520DQ34609440-9F4FB1C4-F2D1-44CD-90E0-8A394DD2429DQ34701492-767A6650-4090-4955-AFB2-BBFD00BB56AFQ34982901-6E6D18D3-B642-4A47-944C-901E11278C39Q35030112-29483EBB-E22A-4C33-B552-1773CC27084CQ35518811-D5CC89B2-68A3-4044-B0EC-76D32EFBBFEDQ35555607-7473EB2C-26F5-4527-BBF8-1B1A84AC2B89Q35798638-FF6AF6EC-82A0-4CAA-B081-B1E540A3BEB4Q36021140-FDB709B8-810A-48F0-82CA-69C66508839BQ36059568-5EF7D0AB-E240-46BC-A4FB-0159CD976C50Q36269106-891A7F21-B918-4736-ABB5-2F41481DF8CDQ36444480-82E53D44-8C5C-408C-9DC0-E20F25C34A14Q36471689-BA9B1461-EE2A-4A7E-986A-E384B7D919B3Q36766056-2D9FE936-A5EB-4B50-B0C5-6BBF2FCDEC14Q36987789-B3066CFD-24BC-44D4-AB26-9E0D6A92C6F2Q37091877-5FFD8433-9B87-40B2-82C0-BA09F878FF8DQ37120841-AC459DF0-078F-46F8-9C76-3834E3EFB71AQ37140546-8F3F5AD8-8D79-4A78-844D-657E0F3D1F5FQ37284234-44310043-7BBF-494A-A97C-17A297DB3768Q37341208-02B15F65-C5E3-4A00-9C7A-28D32F1B590BQ37650570-8ADE1B46-6FA7-485A-BAEA-7796EAA5F0C7Q37697237-0A7697B6-7D81-4AB6-80B0-A493C2C86086Q37700857-FB099A94-3CB2-4CB5-985B-6298474ACCF6Q37989857-2F9D613B-60AA-4B80-B3F1-1EAF89AEC2A5Q38008719-EFB8EF69-19A8-4729-89A6-5E32A204A338Q38026153-94D8A537-783A-40E1-96EC-9012E61984DDQ38033651-1D89E1B7-796B-416D-A735-CD5DADA89F39Q38041396-4BF654FD-9929-4EC7-9FBE-81FD49E2A0F1Q38258564-D660F6AF-8025-49E8-971F-6251718B2579
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinical heterogeneity of drug hypersensitivity.
@ast
Clinical heterogeneity of drug hypersensitivity.
@en
type
label
Clinical heterogeneity of drug hypersensitivity.
@ast
Clinical heterogeneity of drug hypersensitivity.
@en
prefLabel
Clinical heterogeneity of drug hypersensitivity.
@ast
Clinical heterogeneity of drug hypersensitivity.
@en
P1433
P1476
Clinical heterogeneity of drug hypersensitivity.
@en
P2093
Jean-Claude Roujeau
P304
P356
10.1016/J.TOX.2004.12.022
P407
P577
2005-04-01T00:00:00Z